1. Circulating endothelial cells and risk of progression in patients with hepatocellular cancer receiving sorafenib
- Author
-
Graziano Pianezze, Carla Manuppelli, Davide Pastorelli, Petros Giovanis, Massimo Boaretto, and Valter Vincenzi
- Subjects
0301 basic medicine ,Oncology ,Sorafenib ,medicine.medical_specialty ,Hepatocellular cancer ,Hepatology ,Time to progression ,business.industry ,Clinical Trial Perspective ,medicine.disease ,digestive system diseases ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Internal medicine ,Hepatocellular carcinoma ,cardiovascular system ,medicine ,heterocyclic compounds ,In patient ,business ,neoplasms ,medicine.drug - Abstract
Aim: We investigated the behavior of circulating endothelial cells (CEC) in patients with hepatocellular carcinoma (HCC) receiving sorafenib, and whether CEC levels were associated with time to progression (TTP). Materials & methods: CECs in advanced HCC patients receiving sorafenib were counted at baseline and every 4 weeks. Results: Twenty four HCC patients were enrolled in the study. Median TTP was 3.2 months (1–6). Median baseline CEC levels were 67 cells/ml, with an increase of 169.8% after 4 weeks of treatment. Any time CEC levels in patients with a TTP lower than 4 months were higher, but not statistically significant, compared with those in patients with TTP more than 4 months. Conclusion: Treatment with sorafenib changed CEC levels in HCC patients.
- Published
- 2017